FASN Protein Overexpression Indicates Poor Biochemical Recurrence-Free Survival in Prostate Cancer.

Zhi Cao,Jingyi He,Yalong Xu,Fei Guo,Xin Lu,Jin Ji,Huan Xu,Yongwei Yu,Fubo Wang,Xi Chen,Yinghao Sun

doi:10.1155/2020/3904947

Abstract

Backgrounds Fatty acid synthase (FASN) has been regarded as a prognostic marker in prostate cancer (PCa). In this study, we evaluated FASN expression at both mRNA and protein levels and assessed the association between FASN expression and prognosis in male Han Chinese with PCa treated with radical prostatectomy (RP). Methods Expression profile and prognostic value of FASN were analyzed in tissue microarray (TMA) and data retrieved from databases including TCGA public database, GEO database, and our sequencing data with whole clinicopathological characteristics. Results FASN expression was associated with clinical parameters and biochemical recurrence of prostate cancer. The relative expression of FASN mRNA was higher in the tumor tissue in all public databases and our sequencing data (p < 0.001). A similar result was seen in tissue microarray (TMA) (p < 0.001). Analysis of our sequencing data indicated that FASN's relative expression was associated with tumor stage (p = 0.048), and FASN expression was positively associated with the Gleason score (p = 0.004) and seminal vesicle invasion (p = 0.011) in TMA. We found that high FASN expression was an independent predictor of shorter BCR-free survival with univariate and multivariate survival analysis (p < 0.05), rendering FASN an optimal prognostic biomarker in male Han Chinese with prostate cancer. Conclusions Our study demonstrated that FASN was overexpressed at mRNA and protein levels in PCa. We found that patients with high FASN expression had a shorter BCR-free survival, showing its value as a prognostic biomarker in male Han Chinese with PCa.

Highlights

Prostate cancer (PCa) ranks 2nd in male tumor morbidity and 5th in mortality worldwide [1]
In the TCGA database, we found that the relative expression of Fatty acid synthase (FASN) mRNA was significantly higher in tumor tissue compared to benign tissue (p < 0:001, Figure 1(a))
A similar result was observed in our sequencing data and GSE46602: FASN mRNA expression in tumor tissue was relatively high (p < 0:001, Figure 1(d); p < 0:001 Figure 1(g)), but FASN relative expression was not associated with tumor stage in GSE46602 (p = 0:497, Figure 1(h)), while in our sequencing data PCa in pT3 showed higher expression of FASN (p = 0:048, Figure 1(e))

Summary

Introduction

Prostate cancer (PCa) ranks 2nd in male tumor morbidity and 5th in mortality worldwide [1]. According to the latest report, the annual growth rate of PCa morbidity and mortality in China is as high as 7.2% and 5.5%, respectively, making it the fastest-growing tumor in China [2]. PCa was confined to the capsule; radical prostatectomy (RP) or radiotherapy is often recommended [3]. The percentage of PCa patients who undergo radical prostatectomy experiencing biochemical recurrence (BCR) is approximately 25% [4, 5]. Timely and accurate estimation of BCR risk for patients with poor prognosis, especially for those who need adjuvant treatment, is of utmost importance to improve outcomes. The identification of a novel sensitive and specific biomarker to monitor the prognosis of PCa is urgently needed

Methods

Results

Conclusion